Multimeric Biotherapeutics, Inc.
February 11, 2025
Plymouth
Oncology
Multimeric Biotherapeutics, Inc., is a preclinical company that is developing its patented FortiVac vaccine platform technology. FortiVac uses CD40 ligand (CD40L) as a natural adjuvant to activate dendritic cells that in turn elicit very strong CD8+ T cell responses. The initial product is FortiVac-HPV to treat Human Papilloma Virus (HPV)-associated cancers, esp. cervical cancer in the field of women's health. The company seeks funding or a licensing partner to move FortiVac-HPV to the clinic.
)
){kind=logo}
)
){kind=logo}
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}
){kind=logo}